INTRODUCTION
Leukocyte migration across vessel walls and into the surrounding tissue is a characteristic feature of an inflammatory response in physiological host defence and also under pathological scenarios in inflammatory disease states such as myocardial infarction. This process is known to occur via a number of sequential leukocyte responses initiating with the tethering to and rolling of leukocytes on the vascular endothelium 1 . JAM-A is the most widely expressed member of the family and has been shown to be expressed on endothelial and epithelial cells, platelets and on a number of leukocyte subsets 2 . In endothelial and epithelial cells JAM-A locates to the tight junctions where it appears to engage in homophilic binding to JAM-A on adjacent cells, an interaction that in endothelial cells is considered to play a critical role in angiogenesis 2, 7 . The integrin LFA-1 (CD11a/CD18) has also been reported to act as a ligand for JAM-A, an interaction that has been implicated in leukocyte transendothelial cell migration 8 though the role of JAM-A in leukocyte transmigration in vivo requires further clarification.
The involvement of JAM-A in leukocyte transmigration was first reported on by Dejana and colleagues using the neutralising antibody BV-11 5 . Specifically, BV-11 was found to inhibit spontaneous and chemokine-induced monocyte transmigration through cultured endothelial cells and chemokine-induced monocyte migration into murine subcutaneous air pouches 5 . BV-11
was also found to suppress leukocyte recruitment to cerebrospinal fluid following cytokine induced meningitis 9 . Despite these positive effects of JAM-A blockade, other studies reported on the inability of anti-JAM-A antibodies to inhibit leukocyte transmigration. Hence, Shaw et al 10 found that leukocyte transmigration through cultured endothelial cells under flow was not inhibited by another anti-JAM-A antibody, whereas under the same conditions blockade of PECAM-1 did reduce transmigration. In addition, in vivo, BV-11 failed to inhibit leukocyte influx into the meninges following bacterial or viral murine meningitis 11 . More recently, following the generation of JAM-A deficient mice, further evidence has been obtained for the involvement of JAM-A in leukocyte infiltration and leukocyte-mediated tissue damage in murine models of ischemia-reperfusion injury and peritonitis 12, 13 . The aim of the present study was to extend these findings by directly investigating the role of JAM-A in leukocyte transmigration, as observed by intravital microscopy, using both mAb BV-11 and JAM-A deficient mice. Also, as we have previously found that PECAM-1 and ICAM-2 mediate leukocyte transmigration in a stimulus-specific manner 14, 15, 16 , we sought to investigate this possibility in the context of JAM-A. Additionally, the relative functional roles of leukocyte and endothelial cell JAM-A in leukocyte transmigration were investigated by the use of a cell transfer method and mice deficient in endothelial cell JAM-A. Finally, as there exists many overlapping properties in terms of structure, expression profile and function between JAM-A and PECAM-1 17 , the study also investigated the contribution of these proteins and compared their functional roles in the process of leukocyte transmigration. Collectively, the present study provides direct evidence for the involvement of JAM-A in leukocyte migration through venular walls though this effect is stimulus-dependent. Furthermore, in the models employed, JAM-Amediated leukocyte transmigration is largely mediated via endothelial cell JAM-A, and JAM-A and PECAM-1 appear to mediate migration of leukocytes through venular walls at distinct but sequential steps in the transmigration process.
MATERIALS AND METHODS

Animals:
Male (20-25g) C57BL/6 wild-type (WT) mice (Harlan-Olac, Bicester UK), JAM-A deficient
/-) mice and JAM-A -/-/PECAM -/-double knock out (KO) mice were used in this study. The JAM-A -/-and eJAM -/-mice were generated as previously described 13, 18 
Reagents:
Recombinant murine IL-1β was from R&D Systems (Abingdon, Oxford, UK), Calcein-AM was purchased from Molecular Probes (Poortgebouw, The Netherlands), LTB 4 was purchased from Calbiochem (Novabiochem Corporation, La Jolla, CA), PAF (Sigma-Aldrich, Deisenhofen, Germany), control IgG2b and IgG2a antibodies were from Serotec (Oxford, UK) and the anti-PECAM-1 mAb Mec13.3 was from Becton Dickenson (Cowley, Oxford, UK). ICAM-2 mAb 3C4 was from BD Pharmingen (Cowley, Oxford, UK). All other purchased reagents were from Sigma-Aldrich (Deisenhofen, Germany or Poole, Dorset, UK). The blocking anti-JAM-A mAb BV-11 was generated as previously reported 5, 20 .
Intravital microscopy:
Intravital microscopy (IVM) was used to directly observe leukocyte responses within mouse cremasteric venules as previously detailed 15, 21 . Mice were anaesthetised using ketamine and xylazine and the cremaster muscle was surgically exteriorised onto a purpose-built microscope stage and continuously superfused with warm Tyrodes solution 15, 21 . Leukocyte responses were prior to the induction of inflammatory reactions. In selected experiments, mean arterial blood pressure, blood flow velocity and peripheral leukocyte counts were measured, largely as previously detailed 15, 21 and no significant differences in these parameters were noted between the different strains of mice studied or in mice treated with different mAbs (data not shown).
Quantification of fluorescent leukocyte responses:
To enable us to investigate the contribution of leukocyte and endothelial JAM-A in leukocyte transmigration and to assess the potential additive roles of JAM-A-and PECAM- 
Immunofluorescence labelling and analysis of cremaster muscle tissues by confocal microscopy:
To observe the expression patterns of JAM-A and PECAM-1, tissues were immunostained following intravenous and topical application of anti-JAM-A and anti-PECAM-1 mAbs, respectively. Briefly, animals were given an i.v injection of 2 mg/kg of rat anti-mouse BV-11
(anti-JAM-A) or IgG2b (control mAb) and 10 min later the animals were sacrificed using a CO 2 chamber. As the purpose of these experiments was to investigate the expression profile of molecules on endothelial cells, the mice were initially subjected to intravascular washout to remove platelets and leukocytes (which express JAM-A and PECAM-1). The cremaster muscles were then dissected away from the animals and fixed in 4 % paraformaldehyde. Tissues were blocked and permeabilised in PBS containing 20 % normal goat serum and 0.5 % Triton X-100, then incubated with a goat anti-rat Alexa-Fluor-488-conjugated secondary antibody (Molecular Probes, Eugene, OR). After washes, the tissues were incubated with a directly allophycocyanin (APC)-conjugated rat anti-mouse mAb Mec13.3 against PECAM-1 (BD Biosciences, Oxford, UK). Samples were viewed using a Zeiss LSM 5 Pascal confocal laser-scanning microscope equipped with argon and helium-neon lasers incorporating a 40x objective lens (0.75 aperture).
Acquired Z-stack images were used for 3D-reconstruction analysis of whole vessels using the LSM 5 Pascal software (version 3.2; Carl Zeiss Ltd, Welwyn Garden City, UK). For clarity, the image of JAM-A and PECAM-1 vascular expression shown in Figure 5A is the negative of the original, thus enabling expressions of the molecules to be shown in black on a white background.
The position of leukocytes in inflamed cremaster muscle tissues was quantified as previously detailed 22 . Briefly, tissues from WT, JAM-A -/-and PECAM-1 -/-mice were fixed and blocked/permeabilised as described above. The tissues were then immunostained with a marker for neutrophils (rat anti-mouse MRP-14, gift from Dr Nancy Hogg, Cancer Research UK, images of 150 µm lengths of venules (4 vessels per tissue) were acquired by confocal microscopy and analysed using the image processing soft-ware Volocity™ (Improvision, UK).
This soft-ware enables analysis of acquired and reconstructed 3D images at different angles, thus allowing the position of leukocytes relative to the endothelium and the endothelial cell basement membrane to be determined accurately.
Statistics:
Data analysis was performed using the statistical software SigmaStat for Windows (Jandel Scientific, Erkrath, Germany) or Graph-pad Prism 4. All results are expressed as mean ± SEM.
Statistical significance was assessed by one way ANOVA with Student-Newman-Keuls multiple comparison test. Where two variables were analyzed, a Rank Sum test was used. P < 0.05 was considered significant.
RESULTS
JAM-A mediates leukocyte transmigration in a stimulus-specific manner
To directly investigate the role of JAM-A in the multi-step process of leukocyte emigration in vivo, the effect of antibody blockade or genetic deletion of JAM-A on leukocyte responses within mouse cremasteric venules was observed by IVM. Furthermore, to address the potential stimulus-specific role of JAM-A in leukocyte migration, the effect of a number of inflammatory stimuli was investigated.
In WT mice, topical application of the chemoattractant LTB 4 (10 
JAM-A mediates leukocyte migration in response to ischaemia/reperfusion injury at the level of transmigration
The above findings were extended to a more pathological inflammatory scenario and so responses elicited in the cremaster muscle by I/R injury were investigated (30 min of ischaemia followed by 120 min reperfusion, as detailed in Materials & Methods). The resultant effect was a time-dependent increase in leukocyte firm adhesion and transmigration during the reperfusion period ( Figure 3A) . Pretreatment of WT animals with mAb BV-11 prior to induction of I/R injury, resulted in a significant reduction in leukocyte transmigration at 120 min post initiation of reperfusion as compared to control mAb treated mice (89 % inhibition, p < 0.05). 
Endothelial cell JAM-A and not leukocyte JAM-A mediates IL-1β-induced leukocyte transmigration
Since JAM-A is expressed on both leukocytes 13 and endothelial cells and that it may support JAM-A/PECAM-1/ICAM-2-independent neutrophil transmigration.
Other factors may also account for stimulus-specific mechanisms of leukocyte transmigration. Results are presented as mean ± SEM for n = 6 mice/group. Statistically significant differences between control and stimulated groups are shown by asterisks, * P < 0.05, ** P < 0.01 and *** P < 0.001. Additional statistical comparisons are indicated by lines and hash symbols, # P < 0.05. 
